Absci Corporation
NASDAQ:ABSIBiotechnology
+$0.08 today
- Market cap
- $1.41B
- Beta
- 2.46
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$0.77
Volume 5.66M
Average 5.10M
ABSI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Absci CorporationNASDAQ: ABSI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $29.6M (cash outflow) rose 12.3% year over year, ahead of the +10.2% change in trailing-twelve-month net income. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.
Context
- Net income amounted to 4113.7% of revenue in FY2025, up 1839.6 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$107.64M (-6.5%) for the fiscal year ending Dec 2026, a slowdown from the +11.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$29.6M+0.1% QoQ
- Last fiscal yearDec 2025
- -$115.18M+11.7% YoY
- LTMMar 2026
- -$118.44M+10.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.3% | +7.4% | -5.0 pp |
| 1 year | +11.7% | -6.5% | -18.3 pp |
| 3-year CAGR | +3.2% | -4.9% | -8.1 pp |
| 5-year CAGR | -8.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (115.18M) USD
- Year-over-year change
- -11.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (115.18M) | -11.7% |
| FY2024 | 2024-12-31 | (103.11M) | +6.7% |
| FY2023 | 2023-12-31 | (110.57M) | -5.4% |
| FY2022 | 2022-12-31 | (104.9M) | -3.9% |
| FY2021 | 2021-12-31 | (100.96M) | — |
Net Income vs competitors
How ABSI compares with its peers on the latest reported figures
- ABSI's LTM Mar 2026 net income of $118.44M is the smallest of the 3 companies compared; the peer median is $207.21M.
- Its year-over-year change of +10.2% is the lowest of 3, against a peer median of +17.2%.
- Net income amounts to 6450.8% of revenue for ABSI, versus a peer median of 490.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $222.97M | +22.9% | — | 699.1% |
| LTM Sep 2026 | $191.46M | +11.5% | — | 282.2% | |
| LTM Mar 2026 | $118.44M | +10.2% | +3.2% | 6450.8% | |
| Peer median (excluding ABSI) | $207.21M | +17.2% | — | 490.6% | |
Competitors are the stored peer set for ABSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.96M) | (104.9M) | (110.57M) | (103.11M) | (115.18M) |
| Depreciation & Amortization | 6.65M | 13.1M | 14M | 13.39M | 11.74M |
| Deferred Income Tax | (8.9M) | (505K) | (52K) | 0 | 0 |
| Stock-Based Compensation | 10.61M | 12.54M | 11.42M | 19.45M | 18.32M |
| Change in Working Capital | (3.15M) | (1.54M) | 1.52M | (368K) | 423K |
| Accounts Receivables | 230K | (148K) | (666K) | 2.24M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (533K) | (786K) | 2.03M | 1.09M |
| Other Working Capital | (4.95M) | (859K) | 2.97M | (4.63M) | (671K) |
| Other Non-Cash Items | 35.15M | (30K) | 19.05M | (1.77M) | (8.23M) |
| Operating Cash Flow | (60.6M) | (81.34M) | (64.64M) | (72.4M) | (92.93M) |
| Capital Expenditures | (38.05M) | (16.18M) | (860K) | (404K) | (1.11M) |
| Acquisitions (Net) | (28.13M) | (8M) | 0 | 0 | 1.31M |
| Purchases of Investments | (1.2M) | (108.59M) | (147.35M) | (186.11M) | (119.87M) |
| Sales of Investments | 0 | 5M | 229.9M | 144M | 69.5M |
| Other Investing Activities | 0 | 783K | 254K | 939K | 0 |
| Investing Cash Flow | (67.38M) | (126.98M) | 81.94M | (41.58M) | (50.16M) |
| Debt Repayment | 120.85M | 4.58M | (5.35M) | (4.03M) | (3.2M) |
| Common Stock Issued | 210.4M | 656K | 862K | 86.56M | 109.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 336.19M | 5.24M | (4.48M) | 82.53M | 105.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 208.22M | (203.08M) | 12.83M | (31.45M) | (37.14M) |
| Free Cash Flow | (98.65M) | (97.51M) | (65.5M) | (72.81M) | (94.03M) |
Absci Corporation
NASDAQ:ABSI
Intrinsic Alpha fair value
Locked
Current Price
$8.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.